The private labeler is closing its Holland and Montague, Mich.-based manufacturing facilities and will "transfer its profitable product lines" from those locations to plants based in Allegan, Mich. and The Bronx, N.Y., Perrigo announces June 27. The firm will discontinue production for its unsuccessful psyllium-based laxatives and effervescent tablets. The closings correspond with Perrigo's business strategy to improve efficiency and successfully integrate Agis, an Israeli generics firm acquired in March 2005, the firm states. Perrigo estimates an $8 mil. pre-tax charge will be incurred during Q4 2006 (ending July 1) as well as a $3 mil. one-time cost during fiscal 2007 as a result of the plant closings. All 140 employees affected by the closing plants will be offered positions at the Allegan site, Perrigo says...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
A government-backed program is working on improving the ability to run dementia clinical trials in the UK, and access to trials for participants.
Vinay Prasad’s exit from the US FDA reignited conversations about integrating its drugs and biologics centers under George Tidmarsh. Those plans appear to be shelved, but the leadership transition could be an opportunity to fully realize the vision for the Oncology Center of Excellence.
The Pink Sheet viewed Stealth's complete response letter and other documents indicating the FDA appears willing to grant accelerated approval to elamipretide before a confirmatory trial begins enrolling. But the company says it needs a two-month review of the NDA resubmission to survive.
